Instant Download
Your unique download link appears right after you complete your purchase, and is also sent instantly to the email address you provided.
Couldn't load pickup availability
Your unique download link appears right after you complete your purchase, and is also sent instantly to the email address you provided.
978-9819734450
Springer
2024
English
501
4 MB
By Akihiko Gemma This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The bookoffers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies. Product Details Publisher : Springer; 2024th edition (August 2, 2024) Language : English Hardcover : 128 pages ISBN-10 : 9819734452 ISBN-13 : 978-9819734450
